SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
Abstract Background Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aβ immunotherapy-related vasogenic edema...
Main Authors: | Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Patrick Benoit, Pascal Barneoud, Véronique Taupin, Philippe Bertrand, Philippe Dugay, Béatrice Cameron, Yi Shi, Souad Naimi, Marc Duchesne, Marie Gagnaire, Tim Weeden, Tara Travaline, David Reczek, Leonard Khiroug, Mohamed Slaoui, Pascale Brunel, Hidehiro Fukuyama, Jeffrey Ravetch, Thierry Canton, Caroline Cohen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-018-0447-y |
Similar Items
-
Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid-β
by: Elisabet Wahlberg, et al.
Published: (2017-07-01) -
Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid β precursor protein
by: Lorena Heredia, et al.
Published: (2004-08-01) -
Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
by: Pyun JM, et al.
Published: (2021-04-01) -
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
by: Noelia Fandos, et al.
Published: (2017-01-01) -
Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report
by: Kitaguchi N, et al.
Published: (2018-11-01)